AbbVie (ABBV) – Press Releases
-
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
-
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
-
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
-
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
-
SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne
-
AbbVie to Host First-Quarter 2024 Earnings Conference Call
-
Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®
-
NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
-
NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13
-
Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics
-
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
-
U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
-
ALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024
-
AbbVie to Present at the Barclays 26th Annual Global Healthcare Conference
-
AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
-
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
-
JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval
-
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
-
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
-
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
-
Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea
-
AbbVie to Present at the TD Cowen 44th Annual Health Care Conference
-
Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea
-
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
-
U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)
-
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
-
Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity
-
AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
-
BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs
-
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
-
AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)
-
AbbVie Declares Quarterly Dividend
-
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
-
AbbVie Completes Acquisition of ImmunoGen
-
Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases
-
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
-
Allergan Aesthetics Releases "Decoding the Future of Aesthetic Individuality" Exploring the Power of Self-Expression
-
Allergan Aesthetics Showcases Commitment to Individuality, Innovation, and Integrity at IMCAS World Congress 2024
-
Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.
-
AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union
-
Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
-
AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies
-
AbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call
-
AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
iSTAR Medical continues European expansion with first MINIject® surgeries in the Netherlands
-
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
-
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
-
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
-
AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
-
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
Back to ABBV Stock Lookup
